Gilead Sciences has announced more data on the new crown treatment drug Redsivir, including a comparative analysis of the Third Stage SIMPLE-Severe trial. Gilead rose more than 2 percent in early trading. The comparative analysis also showed that by the 14th day, 74.4 percent of patients treated with Redseve recovered, compared with 59 percent of patients receiving standard treatment.
By the 14th day, the mortality rate was 7.6 per cent for patients treated with Redseve, compared with 12.5 per cent for those who did not take the drug.
Gilead also cited a new analysis from the Sympathetic Drug Use Program, which showed that by the 28th day, 83 percent of pediatric patients and 92 percent of pregnant women and postnatal women with multiple diseases recovered.
Gilead analyzed data on the use of Redsivir and hydroxychloroquine.